Literature DB >> 12238144

Local lymph node assay with non-radioisotope alternative endpoints.

Akiko Suda1, Masahiro Yamashita, Mitsuyuki Tabei, Kazuhiko Taguchi, Hans-Werner Vohr, Naohisa Tsutsui, Ritsuyoshi Suzuki, Katsuaki Kikuchi, Keisuke Sakaguchi, Kouki Mochizuki, Kazuichi Nakamura.   

Abstract

The local lymph node assay has recently been accepted by regulatory agencies as a stand-alone alternate method for predicting allergic contact dermatitis. To compare the sensitivity of non-radioisotope methods with that of the standard assay, we determined if these modified methods would affect evaluation of sensitization potency. For this reason, we used 2,4-dinitrochlorobenzene (DNCB) and benzocaine for different sensitizing criteria. Female CBA mice were treated for 3 days with a test compound or vehicle applied to each side of both ears. Bilateral auricular lymph node proliferative activity was assessed by the following endpoints with incorporation of 3H-methyl thymidine (3H-TdR), bromodeoxyuridine (BrdU) in vivo, and BrdU ex vivo, IL-2 production, and proliferating cell nuclear antigen (PCNA) expression. Ear thickness was also tested. The strong sensitizer DNCB was detectable by any of the non-radioisotope endpoints as well as by radioisotope-dependent standard assay. On the other hand, when evaluating the weak sensitizer benzocaine, significant changes were evident in BrdU incorporation ex vivo and in vivo, and IL-2 production. We believe that these non-radioisotope methods can assess allergic contact dermatitis caused by chemicals even in the laboratory, where it can be difficult to handle radioisotopes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12238144     DOI: 10.2131/jts.27.205

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  1 in total

1.  Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.

Authors:  Philippe Azam; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Stephen Griffey; Heike Wulff
Journal:  J Invest Dermatol       Date:  2007-02-01       Impact factor: 8.551

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.